Tianyou Tang^{1*}, Yi Zhong¹, Sipei Xu² and Huilin Yu³

RESEARCH

BMC Pregnancy and Childbirth

Open Access

Causal effects of endometriosis on SLE, RA and SS risk: evidence from meta-analysis and Mendelian randomization



Background Endometriosis is an underdiagnosed disorder that affects an estimated 6-10% of women of reproductive age. Endometriosis has been reported in epidemiological studies to be associated with autoimmune diseases. However, the relationship remains controversial.

Methods A meta-analysis of observational studies was undertaken to evaluate the risk of autoimmune diseases in patients with endometriosis. The relevant studies were retrieved via the databases Medline, Embase and Web of Science until July 20, 2023. Mendelian randomization (MR) was subsequently utilized to scrutinize the causal influence of genetic predisposition toward endometriosis on three autoimmune diseases.

Results The meta-analysis findings revealed a relationship between endometriosis and the onset of SLE (cohort studies: RR = 1.77, 95% confidence interval (CI): 1.47-2.13, I² = 0%; Case-control and cross-sectional studies: OR = 5.23, 95% CI: 0.74-36.98, I² = 98%), RA (cohort studies: RR = 2.18, 95% CI: 1.85-2.55, I² = 92%; Case-control and cross-sectional studies: OR = 1.40, 95% CI: 1.19–1.64, $l^2 = 0\%$) and SS (cohort studies: RR = 1.49, 95% CI: 1.34–1.66, $l^2 = 0\%$). Similarly, in our MR study, the results of the inverse-variance-weighted (IVW) model suggested that genetic predisposition to endometriosis was causally associated with an increased risk for SLE (OR=1.915, 95% CI: 1.204-3.045, p=0.006) and RA (OR = 1.005, 95% CI: 1.001-1.009, p = 0.014).

Conclusions Both our meta-analysis and MR study indicate that endometriosis increases the risk of autoimmune diseases. These findings not only broaden our understanding of the genetic mechanisms underlying the comorbidity of endometriosis and autoimmune diseases, but also offer a new strategy for autoimmune disease prevention.

Keywords Endometriosis, Systemic lupus erythematosus (SLE), Rheumatoid arthritis (RA), Sjögren's syndrome (SS), Meta-analysis, Mendelian randomization

*Correspondence:

Tianyou Tang

2020210155@stu.cgmu.edu.cn

Children's Hospital of Chongqing Medical University, Chongqing, China ² The First Medicine College, Chongqing Medical University, Chongqing,

China

³ The Second Medicine College, Chongqing Medical University, Chongqing, China

Introduction

Endometriosis is an estrogen-dependent chronic inflammatory disease that affects approximately 7-10% of women worldwide. It is characterized by two main symptoms: pelvic pain and infertility [1]. Serval studies have indicated that endometriosis is associated with numerous diseases, including gastrointestinal diseases, malignancies, cardiovascular diseases, mental disorders and autoimmune diseases [2, 3]. The pathogenesis of endometriosis remains unclear, but the retrograde menstruation theory is currently widely accepted [4].



© The Author(s) 2024. Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.

Autoimmune diseases affect 3–5% of the population, with some being organ-specific, like RA, and others involving multiple organs, such as SLE [5]. There have been many review articles discussing the immunological aspects of endometriosis [6, 7]. They believe that the changes in cell-mediated and humoral immunity in patients with endometriosis may be the reason for the increased risk of autoimmune diseases. However, there are few articles based on population-based observational studies. In an attempt to understand more about the risk of autoimmune diseases in endometriosis, we embarked on a meta-analysis by including cohort studies, cross-sectional studies and case–control studies.

Mendelian randomization (MR) analysis employs genetic variation as an instrumental variable, enabling the evaluation of relationships between an exposure and an outcome. By leveraging the random distribution of genetic variation, MR helps eliminate confounding factors and reverse causation, thus simulating the randomization process seen in a randomized controlled experiment [8–10]. The degree of the connection and the direction of causality between endometriosis and autoimmune diseases were evaluated in this study using MR. In this study, we employed a meta-analysis in conjunction with MR analysis to elucidate the causal relationship, strength of association, and direction of causality between endometriosis and three autoimmune diseases.

Methods

Meta-analysis

General information

We performed this meta-analysis following the Preferred Reporting Items for Systematic Reviews and Meta-analyses (PRISMA) guidelines [11]. The study protocol was registered at PROSPERO (CRD42023444650). (https://www.crd.york.ac.uk/PROSPERO/).

Search strategy

A search strategy was developed as presented in (Datasheet1: Table S1). Two researchers (TYT and YZ) conducted a comprehensive electronic literature search of the PubMed, Web of Science, and Embase databases from their inception until July 2023. No restrictions were applied regarding geographic area, language, or publication status. Additionally, the researchers manually reviewed the reference lists of relevant articles to identify any additional studies that may have been missed in the initial search.

Study selection

Two of the authors (TYT and YZ) initially screened the titles and abstracts of the studies to exclude those that appeared irrelevant. Then, they thoroughly read the full

texts of the remaining studies to further exclude any studies that did not meet the eligibility criteria. Any disagreements between the two authors were resolved through discussion.

Eligible articles for this study had to satisfy the following criteria: 1) having a cohort, case-control or cross-sectional study design and published in English, 2) comparing the risk of autoimmune disease among women with/without endometriosis, 3) providing data on odds ratio (OR), risk ratio (RR), hazard ratio (HR), standardized incidence ratio (SIR), incidence rate ratio (IRR) for autoimmune disease. (Table 1).

Data extraction

Two authors (TYT and YZ) independently extracted data and a consensus was reached in case of any inconsistency.

Using a pre-designed data extraction form, the following information was meticulously recorded: title, the name of the primary author, publication year, country, average age, duration of follow-up, sample size, outcome assessment, risk estimate, corresponding 95% confidence intervals.

Assessing the Risk of Bias.

The Newcastle-Ottawa quality assessment scale (NOS) was used to evaluate the methodological quality of cohort study and case-control study included in the analysis [12]. In the absence of established standard criteria, we categorized studies with 0-3 stars, 4-6 stars, or 7-9 stars as low-quality, moderate-quality, or high-quality, respectively. To evaluate the methodological quality of cross-sectional studies, we used the criteria provided by the Agency for Healthcare Research and Quality (AHRQ) [13]. Each item in the assessment was assigned a score of '0' if it was answered as 'NO' or 'UNCLEAR', and a score of '1' if it was answered as 'YES'. The total score for each study was then calculated. Based on the total score, the article quality was categorized as low-quality (0-3), moderate-quality (4-7), or high-quality (8-11). Disagreements were resolved through discussion.

Table 1 PICOS criteria for inclusion of stud	dies
--	------

Participants	The general population
Intervention/exposure	Endometriosis
Comparison	People without endometriosis
Outcome	Autoimmune diseases risk
Study design	Cohort, case–control and cross-sectional study

Statistical analysis

The meta-analysis was conducted using Review Manager 5.4. For cross-sectional and case-control studies, raw data were extracted to compute a odds ratio (OR) accompanied by 95% confidence intervals (CIs). For cohort studies, SIR, IRR and HR were treated as the relative risk (RR), and the pooled RR with a 95% confidence interval was calculated [14, 15]. To ensure a more accurate assessment of the relationships between endometriosis and SLE, RA and SS, categorical meta-analyses were conducted. The I2 statistic was used to evaluate the degree of heterogeneity among the included studies. If the I2 value exceeded 50% or the p-value was less than 0.05, indicating a high level of heterogeneity, a random-effects model was employed. Conversely, if the I2 value was below 50% or the p-value was greater than or equal to 0.05, a fixed-effect model was used in the meta-analysis. This approach helps to account for heterogeneity and provide more reliable results.

Mendelian randomization

Study design

The Mendelian randomization (MR) method is based on three key assumptions, which are summarized in Fig. 1. First, the selected SNPs must be significantly correlated with the exposure factor. Second, SNPs must be independent of potential confounding factors. Third, SNPs should not have a direct association with outcome.

Data source

For the study of endometriosis, we retrieved genomewide association study (GWAS) summary data from Nilufer R et al. (PMID: 36,914,876) [16]. In this GWAS, a total of 60,694 patients with endometriosis and 701,926 controls of European and East Asian descent were included by the authors. Summary statistics of SLE are from Wang YF et al. (PMID: 33,536,424), including up to 12,653 participants (4,222 cases and 8,431 controls) of East Asian ancestry [17]. Summary statistics of RA are from Neale Lab, including up to 337,159 participants (3,730 cases and 333,429 controls) of European ancestry. The summary statistics of SS were obtained from the FinnGen consortium release data (1,290 cases and 213,145 controls).

Statistical analysis

Cochran's Q test was used in this MR study to determine whether there was variability in estimates of specific genetic variants [18]. Inverse variance weighted (IVW) analysis was the main technique employed [19]. In addition to IVW, further analyses were carried out utilizing the weighted median method [20], simple mode, weighted mode, and MR-egger regression method [21]. Finally, to guarantee the accuracy of the results, we tested and calibrated horizontal pleiotropic outliers in the IVW model using MR pleiotropy residual sum and outlier (MR-PRESSO) [22].




Fig. 1 Diagram for key assumptions of MR analyses. Exposure SNPs were used as the genetic instruments to investigate the causal effect of endometriosis on outcome. The directional arrows indicates that the genetic instruments (SNPs) are associated with the exposure and can only influence the outcome through the exposure. Dashed lines represent that the genetic instruments (SNPS) are independent of any confounding variables affecting the results

Sensitivity analysis

To detect potential pleiotropy, we conducted the MR-Egger test and interpreted a P-value greater than 0.05 for the MR-Egger intercept as an absence of horizontal pleiotropy [23]. To assess the stability of the results, leave-one-out sensitivity analyses were conducted, wherein a single SNP was excluded in each iteration. This analysis helps determine if any single SNP is driving the observed associations. Funnel plots and forest plots were generated to visually explore the existence of pleiotropy, which is when a genetic variant affects multiple traits or outcomes. A two-sided p-value of less than 0.05 was considered as suggestive of significance. All the analyses were performed using the "Two-Sample-MR" and "MR-PRESSO" packages in R software, specifically Version 4.2.3.

Results

Meta-analysis

Study selection and characteristics

A flowchart of the process of choosing the specific literature is shown in Fig. 2. Tables 2 and 3 provide a

detailed summary of key features for the 13 included research. In brief, 3 (23.1%) investigations were conducted in North America, 4 (30.8%) in Europe, and 6 (46.2%) in Asia. In terms of study design, one (7.8%) study was cross-sectional, four (30.8%) were case– control studies, and eight (61.5%) were cohort studies (four prospective cohort studies and four retrospective cohort studies).

Quality assessment

According to the information provided, the researchers used the Agency for Healthcare Research and Quality (AHRQ) rating criteria to assess the quality of crosssectional studies included in their analysis. Additionally, the Newcastle–Ottawa Scale (NOS) was used to evaluate the quality of case–control and cohort studies. The results of this assessment can be found in Tables 4 and 5, which presumably shows that all the publications included in the study were rated as high or moderate quality based on the use of AHRQ and NOS criteria.




Fig. 2 The flowchart of meta-analysis

Citation	Country	Country Study period	Study design	Effect estimates	Study population (<i>n</i>)	Diagnosis criteria	
						Endometriosis	Autoimmune disease
Matorras et al. (2007) [27]	Spain	1990- 2004	Case–control study	SLE: OR = 2.9 (95%Cl:0.27-32.57) P > 0.05 SS: OR \cdot 95%Cl:not calculable P > 0.05	Case: 342 Control: 501	Histology	Clinical interview and medical records according to the ACR criteria
Yoshii et al. (2021) [31]	Japan	2011- 2018	Case–control study	SLE: IRR = 1.35 (95%CI:0.99-1.84) RA: IRR = 1.31 (95%CI:1.05-1.64)	Case: 30,516 Control: 120,976	ICD-10-CM	ICD-10-CM
Porpora et al. (2019)	Italy	2014- 2017	Retrospective case–control study	SLE: OR=8.63 (95%Cl:1.07-69.91) P=0.01	Case: 148 Control: 150	Laparoscopy and histology	Antinuclear anti- bodies, extractable nuclear antigen, anti-cardiolipin anti- bodies, antiphos- pholipid antibodies, and lupus antico- agulant
Sinaii et al. (2002) [30]	USA, Canada	1988	Cross-sectional study	SLE: OR = 20.7 (95%Cl:14.3-29.9) P < 0.0001 RA: OR = 1.5 (95%Cl:1.2-1.9) P = 0.001 SS: OR = 23.9 (95%Cl:15.5-36.5) P < 0.0001	Study sample: 3680	Self-reports of laparoscopy/ laparotomy	Self-reported physi- cian diagnosis

Table 2 Characteristics of case-control and cross-sectional studies

Data synthesis

Endometriosis and SLE Eight studies were included in a meta-analysis comparing the risk of SLE in individuals with endometriosis and those without endometriosis, involving 477,501 individuals and 113,318 endometriosis cases [24–31]. For case–control and cross-sectional studies, we did not find a significant association between the two conditions. For cohort studies, with low heterogeneity, the pooled risk of SLE was greater in individuals with endometriosis than in those without endometriosis (RR=1.77, 95% CI 1.47–2.13; I2=0%) (Fig. 3).

Endometriosis and RA Six studies were included in a meta-analysis comparing the risk of RA in individuals with endometriosis and those without endometriosis, involving 434,377 individuals and 73,006 endometriosis cases [25, 30–34]. Case–control and cross-sectional studies have described the association between endometriosis and RA (OR=1.40, 95% CI 1.19–1.64; I2=0%). For cohort studies, with high heterogeneity, we observed similar trends in the results (RR=1.89, 95% CI 1.04–3.42; I2=92%) (Fig. 3).

Endometriosis and SS Three studies were included in a meta-analysis comparing the risk of SS in individuals with endometriosis and those without endometriosis, involving 215,006 individuals and 56,074 endometriosis cases [28, 30, 35]. For cohort studies, with low heterogeneity, the pooled risk of SS was greater in individuals with endometriosis than in those without endometriosis (RR = 1.49, 95% CI 1.34–1.66; I2 = 0%) (Fig. 3).

Mendelian randomization study

Genetic associations between endometriosis and SLE, RA, and SS risk

Using the random-model IVW, we discovered a link between each standard rise in endometriosis risk and a faster development to SLE (OR=1.915, 95% CI: 1.204–3.045, p=0.006) and RA (OR=1.005, 95% CI: 1.001–1.009, p=0.014). However, no causal relationship was found between endometriosis and SS. (Fig. 4).

Sensitivity analysis

Cochran's Q test findings revealed that these SNPs exhibited no heterogeneity. We found no evidence of

Citation Country	Country	Study period	Study design	Effect estimates		Diagnosis criteria	
				population (<i>n</i>)	Endometriosis	Autoimmune disease	
Nielsen et al. (2011) [28]	Denmark	1977- 2007	Retrospective cohort study; 12.1 years follow-up	SLE: SIR:1.6 (95%Cl:1.2–2.1) SS: SIR:1.6 (95%Cl:1.3–2.0)	Exposure: 37,661	ICD8:codes 62,530–62539 ICD10: code group N80	Medical records according to the ACR criteria
Harris et al. (2016a) [25]	USA	1989- 2011	Prospective cohort study; 22 years follow-up	SLE: HR = 1.61 (95%Cl:0.88-2.92) P<0.05 RA: HR = 1.16 (95%Cl:0.84-1.59) P<0.05	Exposure: 6434 Control: 108,019	Self-reported laparoscopy	Medical records according to the ACR criteria
Lin et al. (2020) [26]	Taiwan	2000- 2012	Retrospective cohort study; patients were followed until diagnosed with SLE, death(means = 8.1 years)	SLE: HR = 1.86 (95%CI:1.36–2.53) P < 0.0001	Exposure: 17,779 Control: 17,779	ICD-9-CM	Medical records according to board-certified rheumatologists
Fan et al. (2021) [<mark>24</mark>]	Taiwan	2000- 2011	Retrospective cohort study; 12 years follow-upar	SLE: HR = 2.37 (95%Cl:1.35-4.14)	Exposure: 16,758 Control: 16,758	ICD-9-CM	ICD-9-CM
Merlino et al. (2003) [<mark>33</mark>]	USA	1986- 1997	Prospective cohort study; 11 years follow-up	RA: RR = 1.59 (95%CI:0.82-3.08)	/	Self-reported physician diag- nosis	Self-reported phy- sician diagnosis
Chen et al. (2020)	Taiwan	2000- 2012	Prospective cohort study; patients was followed until the appearance of RA, their removal from the NHIP, death, or the end of 2013 (means = 8.1 years)	RA: HR = 3.71 (95%Cl: 2.91-5.73) P=0.77	Exposure: 17,913 Control: 17,913	ICD-9-CM	ICD-9-CM
Xue et al. (2020)	Taiwan	2000- 2013	Prospective cohort study; 13 years follow-up	RA: HR = 1.75 (95%Cl: 1.27-2.41) P < 0.05	Exposure: 14,463 Control: 14,463	ICD-9-CM	ICD-9-CM
Chao et al. (2022) [<mark>35</mark>]	Taiwan	2000- 2012	Retrospective cohort study	SS: HR = 1.45 (95%Cl:1.27–1.65) <i>P</i> < 0.001	Exposure: 14,733 Control: 58,932	ICD-9-CM	ICD-9-CM

directional pleiotropy using MR Egger intercepts and MR-PRESSO (Datasheet 2). The leave-one-out analysis produced a stable result when each SNP was eliminated, as shown in Datasheet 3.

Discussion

Many previous studies have found a link between endometriosis and autoimmune disorders, a literature review was compiled on the topic (Datasheet1:Table S2). We employ meta-analysis and MR to investigate causative associations between endometriosis and SLE, RA, and SS risk. To our knowledge, the latest and probably only meta-analysis was published in 2019 [36]. Due to the inability of cross-sectional and case–control studies to resolve the issue of the temporal relationship between endometriosis and autoimmune diseases, their research faced challenges in determining the sequence of disease development and manifestation, as well as potential causal relationships. Compared to this study, our study comprises more studies in patients with endometriosis, including newer and larger cohort studies. We aimed to investigate the causal effect of endometriosis on SLE, RA and SS. As the first report to employ MR in investigating the causal association between endometriosis and the risk of SLE, RA, and SS, our study eliminates

Author	Selection	Comparability	Exposure	Total score	Quality grade
Nielsen et al. (2011) [28]	2	1	3	6	moderate
Harris et al. (2016a) [25]	1	2	3	7	high
Lin et al. (2020) [<mark>26</mark>]	4	1	2	7	high
Fan et al. (2021) [24]	4	2	3	9	high
Merlino et al. (2003) [33]	4	2	3	9	high
Chen et al. (2020)	4	1	2	7	high
Xue et al. (2020)	4	2	3	9	high
Chao et al. (2022) [35]	3	2	2	7	high
Matorras et al. (2007) [27]	3	1	3	7	high
Porpora et al. (2019)	2	1	3	6	moderate
Yoshii et al. (2021)	2	2	2	6	moderate

Table 4 NOS assessment for case-control and cross-sectional studies

 Table 5
 AHRQ assessment for cross-sectional studies

Agency for Healthcare Research and Quality			
Author	Total score	Quality grade	
Sinaii et al. (2002) [<mark>30</mark>]	6	moderate	
Shafrir et al. (2021)	8	high	

confounding factors and reverse causality effects, which may yield more reliable results.

The meta-analysis findings reveal that endometriosis patients are more likely to develop SLE and SS, which is consistent with the results of the meta-analysis from 2019. However, in contrast to previous studies, we found that endometriosis also increases the risk of RA. The discrepancy in findings between the two studies may be due to the fact that the 2019 study only had two cohort studies available for inclusion. We observed that only a limited number of studies accounted for the effects of confounding factors, which may influence the level of the risk. Smoking, alcohol usage, caffeine consumption, and a lack of exercise have all been linked to an increased risk of endometriosis [37]. These lifestyle and environmental factors have also been linked to an increased susceptibility to cancer occurrence [38]. At the same time, the number of included studies was relatively small, which poses a risk of generating spurious associations. Therefore, we encourage more researchers to further investigate the association by employing prospective cohort study designs.

We also utilize a two-sample MR approach to further investigate the impact of endometriosis on the risk of autoimmune diseases. We employ independent loci associated with endometriosis identified from the largest available genome-wide association studies (GWAS) to date. All SNPs were identified in the PhenoScanner database (http://www.phenoscanner.medschl.cam.ac.uk/) to exclude SNPs related to confounding factors. With MR, we found that endometriosis is linked with a higher risk of SLE and RA, which supports prior meta-analyses.

The imbalance of the immune system may explain the the observed impact of endometriosis on autoimmune diseases in clinical practice [39–41]. Previous studies have demonstrated that elevated expression of IL-6, IL-15, and TGF- β 1 in patients with endometriosis can reduce the activity of NK cells [42–44]. It has been observed that patients with endometriosis often have an increase in neutrophils and macrophages in their peritoneal fluid [45, 46]. In the latest meta-analysis to date, Riccio et al. suggested that there is an increase in B lymphocytes and excessive production of autoantibodies in endometriosis [47]. These alterations play an important role in mediating the pathogenesis of autoimmune diseases [48–50].

Estrogen also plays an important role in the development of endometriosis and autoimmune diseases. Endometriosis is an estrogen-dependent disease, and the disruption of estrogen signaling leads to hormonal imbalance, which causes its symptoms [51]. Targeting estrogen is still considered the optimal approach for controlling the progression and inflammation of endometriosis [52]. Estrogen has also been found to regulate the immune system and contribute to the transduction pathways of autoimmunity by activating its nuclear receptor AhR [53]. Estrogen raises the risk of autoimmune diseases by raising the generation of type 1 interferon and promoting the survival of B cells that create pathogenic IgG autoantibodies [54].

Firstly, pleiotropy has always been an important issue in Mendelian randomization. However, neither

Study or Subgroup log[Oc 1.1.1 Case-control study	Ids Ratio] S	E Weight	Odds Ratio IV. Random. 95% C		s Ratio om, 95% Cl
	ius Ratioj c	<u>⊂ weight</u>	IV, Random, 95% C	I IV, Kallu	011, 95% 01
Yoshii et al. 2021	0.3001 0.158	2 29.0%	1.35 [0.99, 1.84]		-
Matorras et al. 2007	1.0907 1.220		2.98 [0.27, 32.57]		
Porpora et al. 2019 Subtotal (95% CI)	2.1552 1.067	3 21.9% 71.1%	8.63 [1.07, 69.90] 2.18 [0.74, 6.42]		
Heterogeneity: Tau ² = 0.44; Chi	i ² = 3 33 df = 2 (
Test for overall effect: Z = 1.42		0.13), 1	- 40 %		
1.1.2 Cross-sectional study					
Sinaii et al. 2002	3.0301 0.187	6 28.9%	20.70 [14.33, 29.90]		—
Subtotal (95% CI)		28.9%	20.70 [14.33, 29.90]		•
Heterogeneity: Not applicable					
Test for overall effect: Z = 16.15	5 (P < 0.00001)				
Total (95% CI)		100.0%	5.23 [0.74, 36.98]		
Heterogeneity: Tau ² = 3.41; Chi		3 (P < 0.000	01); I ² = 98%	0.01 0.1	1 10 10
Test for overall effect: Z = 1.66		1 (D = 0.00)	01) 12 - 02 20/	Endometriosis	Endometriosis-free
Test for subgroup differences: 0	Jni- = 14.94, di -	1 (P = 0.00	01), 1- = 93.3%		
			Risk Ratio	Risk	Ratio
	lisk Ratio]	SE Weight	IV, Fixed, 95% CI	IV, Fixe	d. 95% Cl
1.2.1 Cohort study					
Fan et al. 2021	0.8629 0.28				
Harris et al. 2016 Lin et al. 2020	0.4762 0.30				
Nielsen et al. 2011	0.6206 0.1				-
Subtotal (95% CI)	0.47 0.14	100.0%			•
Heterogeneity: Chi ² = 1.72, df	= 3 (P = 0.63); I		,		
Test for overall effect: Z = 5.96					
		100.00	1 77 [1 47 0 40]		•
Total (95% CI) Heterogeneity: Chi ² = 1.72, df	= 3 (P = 0.63)- 1	100.0% 2 = 0%		·	· ·
Test for overall effect: Z = 5.96		- 0.70		0.01 0.1	1 10 10
Test for subgroup differences:				Endometriosis	Endometriosis-free
0 - F					
			Odds Ratio		ds Ratio
Study or Subgroup log[Oc 2.1.1 Case-control study	ads Ratio] S	⊨ Weight	IV, Fixed, 95% CI Ye	ar IV, Fi	xed, 95% Cl
Yoshii et al. 2021	0.27 0.114	6 52.5%	1.31 [1.05, 1.64] 202	21	-
Subtotal (95% CI)	0.27 0.114	52.5%	1.31 [1.05, 1.64]		•
Heterogeneity: Not applicable			• • •		
Test for overall effect: Z = 2.36	(P = 0.02)				
2.1.2 Cross-sectional study	0.4055 0.400	6 47 50/	1 60 [1 10 4 00] 001	12	-
Sinaii et al. 2002 Subtotal (95% CI)	0.4055 0.120	6 47.5% 47.5%	1.50 [1.18, 1.90] 200 1.50 [1.18, 1.90]	JZ	
Heterogeneity: Not applicable		-1.0%			1
Test for overall effect: Z = 3.36	(P = 0.0008)				
T-4-1 (05% OI)		400.0%	4 40 14 40 4 641		
Total (95% CI) Heterogeneity: Chi ² = 0.66, df =	1 (P = 0 42)· I ² =	100.0%	1.40 [1.19, 1.64]	⊢−−− +−−−	▼
				0.01 0.1	1 10 10
	(P < 0.0001)				
Test for overall effect: Z = 4.02 Test for subgroup differences: 0			I ² = 0%	Endometriosi	
Test for overall effect: Z = 4.02				Endometriosi	s Endometriosis-free
Test for overall effect: Z = 4.02 Test for subgroup differences: 0 Study or Subgroup log[Ris	Chi ² = 0.66, df =	I (P = 0.42),	l² = 0% Risk Ratio V. Random. 95% CI Y∉	Endometriosi R	
Test for overall effect: Z = 4.02 Test for subgroup differences: 0 Study or Subgroup log[Ris 2.2.1 Cohort study	Chi² = 0.66, df = - sk Ratio] SE	l (P = 0.42), Weight I	Risk Ratio V. Random, 95% CI Ye	Endometriosi R ear IV. Ra	s Endometriosis-free
Test for overall effect: Z = 4.02 Test for subgroup differences: (Study or Subgroup log[Ris 2.2.1 Cohort study Merlino et al. 2003	Chi ² = 0.66, df =	I (P = 0.42), <u>Weight I</u> 20.9%	Risk Ratio V. Random. 95% CI Ye 1.59 [0.82, 3.08] 20	Endometriosi R ear IV, Ra	s Endometriosis-free
Test for overall effect: Z = 4.02 Test for subgroup differences: (Study or Subgroup log[Ris 2.2.1 Cohort study Merlino et al. 2003 Harris et al. 2016	Chi ² = 0.66, df = - k Ratio] SE 0.4637 0.3379 0.1484 0.1622	I (P = 0.42), <u>Weight I</u> 20.9% 26.1%	Risk Ratio V. Random, 95% CI Ye 1.59 [0.82, 3.08] 20 1.16 [0.84, 1.59] 20	Endometriosi R ear IV. Ra 103 116	s Endometriosis-free
Test for overall effect: Z = 4.02 Test for subgroup differences: (<u>Study or Subgroup log[Ris</u> 2.2.1 Cohort study Merlino et al. 2003 Harris et al. 2016 Chen et al. 2020	Chi ² = 0.66, df =	I (P = 0.42), Weight I 20.9% 26.1% 26.9%	Risk Ratio V. Random, 95% Cl Yı 1.59 [0.82, 3.08] 20 1.16 [0.84, 1.59] 20 3.71 [2.91, 4.73] 20	Endometriosi R ear IV. Ra 103 1/16 1/20	s Endometriosis-free
Test for overall effect: Z = 4.02 Test for subgroup differences: 0 <u>Study or Subgroup log[Ris</u> 2.2.1 Cohort study Merrino et al. 2003 Harris et al. 2016 Chen et al. 2020 Xue et al. 2020	Chi ² = 0.66, df = k Ratio] SE 0.4637 0.3379 0.1484 0.1622 1.311 0.1239	I (P = 0.42), <u>Weight I</u> 20.9% 26.1%	Risk Ratio V. Random, 95% CI Ye 1.59 [0.82, 3.08] 20 1.16 [0.84, 1.59] 20	Endometriosi R ear IV. Ra 103 1/16 1/20	s Endometriosis-free
Test for overall effect: Z = 4.02 Test for subgroup differences: (Study or Subgroup log[Ris 2.2.1 Cohort study Merino et al. 2003 Harris et al. 2016 Chen et al. 2020 Xue et al. 2020 Subtotal (95% CI) Heterogeneity: Tau ² = 0.33; Chi	Chi ² = 0.66, df = (k Ratio] SE 0.4637 0.3379 0.1484 0.1622 1.311 0.1239 0.5596 0.1636 ² = 36.22, df = 3 (Weight I 20.9% 26.1% 26.9% 26.1% 100.0%	Risk Ratio V. Random. 95% CI Ye 1.59 [0.82, 3.08] 20 1.16 [0.84, 1.59] 20 3.71 [2.91, 4.73] 20 1.75 [1.27, 2.41] 20 1.89 [1.04, 3.42]	Endometriosi R ear IV. Ra 103 1/16 1/20	s Endometriosis-free
Test for overall effect: Z = 4.02 Test for subgroup differences: (Study or Subgroup log[Ris 2.2.1 Cohort study Merino et al. 2003 Harris et al. 2016 Chen et al. 2020 Xue et al. 2020 Subtotal (95% CI) Heterogeneity: Tau ² = 0.33; Chi	Chi ² = 0.66, df = (k Ratio] SE 0.4637 0.3379 0.1484 0.1622 1.311 0.1239 0.5596 0.1636 ² = 36.22, df = 3 (Weight I 20.9% 26.1% 26.9% 26.1% 100.0%	Risk Ratio V. Random. 95% CI Ye 1.59 [0.82, 3.08] 20 1.16 [0.84, 1.59] 20 3.71 [2.91, 4.73] 20 1.75 [1.27, 2.41] 20 1.89 [1.04, 3.42]	Endometriosi R ear IV. Ra 103 1/16 1/20	s Endometriosis-free
Test for overall effect: 2 = 4.02 Test for subgroup differences: 0 Study or Subgroup log[Ris 2.2.1 Cohort study Merlino et al. 2003 Harris et al. 2016 Chen et al. 2020 Subtotal (95% Cl) Heterogeneity: Tau ² = 0.33; Chi Test for overall fect: Z = 2.09 (Total (95% Cl)	chi² = 0.66, df = k Ratio] SE 0.4637 0.3379 0.1484 0.1622 1.311 0.1239 0.5596 0.1636 ² = 36.22, df = 3 (P = 0.04)	I (P = 0.42), Weight I 20.9% 26.1% 26.9% 26.1% 100.0% P < 0.00001; 100.0%	Risk Ratio V. Random. 95% CI Yı 1.59 [0.82, 3.08] 2C 1.16 [0.84, 1.59] 2C 3.71 [2.91, 4.73] 2C 1.75 [1.27, 2.41] 2C 1.89 [1.04, 3.42] 1.89 [1.04, 3.42]	Endometriosi R ear IV. Ra 103 1/16 1/20	s Endometriosis-free
Test for overall effect: Z = 4.02 Test for subgroup differences: (Study or Subgroup log(Ris 2.2.1 Cohort study Merlino et al. 2003 Harris et al. 2016 Chen et al. 2020 Subtotal (95% CI) Heterogeneity: Tau ² = 0.33; Chi' Test (95% CI) Heterogeneity: Tau ² = 0.33; Chi'	Chi² = 0.66, df = SE 0.4637 0.3379 0.1484 0.1622 1.311 0.1239 0.5596 0.1636 ² = 36.22, df = 3 (P = 0.04) 2²	I (P = 0.42), Weight I 20.9% 26.1% 26.9% 26.1% 100.0% P < 0.00001; 100.0%	Risk Ratio V. Random. 95% CI Yı 1.59 [0.82, 3.08] 2C 1.16 [0.84, 1.59] 2C 3.71 [2.91, 4.73] 2C 1.75 [1.27, 2.41] 2C 1.89 [1.04, 3.42] 1.89 [1.04, 3.42]	Endometriosi R R IV. Ra 103 116 120 120 120	s Endometriosis-free
Test for overall effect: Z = 4.02 Test for subgroup differences: (Study or Subgroup log[Ris 2.2.1 Cohort study Merrino et al. 2003 Harris et al. 2016 Chen et al. 2020 Stude et al. 2020 Subtotal (95% CI) Heterogeneity: Tau² = 0.33; Chi Test for overall effect: Z = 2.09 (Total (95% CI) Heterogeneity: Tau² = 0.33; Chi Test for overall effect: Z = 2.09 (Total (95% CI)	Chi² = 0.66, df = (ak Ratio] SE 0.4637 0.3379 0.1484 0.1622 1.311 0.1239 0.5596 0.1636 2" = 36.22, df = 3 ((P = 0.04)	I (P = 0.42), Weight I 20.9% 26.1% 26.9% 26.1% 100.0% P < 0.00001; 100.0%	Risk Ratio V. Random. 95% CI Yı 1.59 [0.82, 3.08] 2C 1.16 [0.84, 1.59] 2C 3.71 [2.91, 4.73] 2C 1.75 [1.27, 2.41] 2C 1.89 [1.04, 3.42] 1.89 [1.04, 3.42]	Endometriosi R R IV. Ra 103 116 120 120 120 120	s Endometriosis-free
Test for overall effect: Z = 4.02 Test for subgroup differences: (Study or Subgroup log[Ris 2.2.1 Cohort study Merrino et al. 2003 Harris et al. 2016 Chen et al. 2020 Stude et al. 2020 Subtotal (95% CI) Heterogeneity: Tau² = 0.33; Chi Test for overall effect: Z = 2.09 (Total (95% CI) Heterogeneity: Tau² = 0.33; Chi Test for overall effect: Z = 2.09 (Total (95% CI)	Chi² = 0.66, df = (ak Ratio] SE 0.4637 0.3379 0.1484 0.1622 1.311 0.1239 0.5596 0.1636 2" = 36.22, df = 3 ((P = 0.04)	I (P = 0.42), Weight I 20.9% 26.1% 26.9% 26.1% 100.0% P < 0.00001; 100.0%	Risk Ratio V. Random. 95% CI Yı 1.59 [0.82, 3.08] 2C 1.16 [0.84, 1.59] 2C 3.71 [2.91, 4.73] 2C 1.75 [1.27, 2.41] 2C 1.89 [1.04, 3.42] 1.89 [1.04, 3.42]	Endometriosi aar IV. Ra 103 106 120 120 120 10.01 0.01 0.1	s Endometriosis-free
Test for overall effect: Z = 4.02 Test for subgroup differences: (Study or Subgroup log[Ris 2.2.1 Cohort study Merrino et al. 2003 Harris et al. 2016 Chen et al. 2020 Stude et al. 2020 Subtotal (95% CI) Heterogeneity: Tau² = 0.33; Chi Test for overall effect: Z = 2.09 (Total (95% CI) Heterogeneity: Tau² = 0.33; Chi Test for overall effect: Z = 2.09 (Total (95% CI)	Chi² = 0.66, df = (ak Ratio] SE 0.4637 0.3379 0.1484 0.1622 1.311 0.1239 0.5596 0.1636 2" = 36.22, df = 3 ((P = 0.04)	I (P = 0.42), Weight I 20.9% 26.1% 26.9% 26.1% 100.0% P < 0.00001; 100.0%	Risk Ratio V. Random. 95% CI Yı 1.59 [0.82, 3.08] 2C 1.16 [0.84, 1.59] 2C 3.71 [2.91, 4.73] 2C 1.75 [1.27, 2.41] 2C 1.89 [1.04, 3.42] 1.89 [1.04, 3.42]	Endometriosi aar IV. Ra 103 106 120 120 120 10.01 0.01 0.1	s Endometriosis-free
Test for overall effect: Z = 4.02 Test for subgroup differences: (Study or Subgroup log[Ris 2.2.1 Cohort study Merlino et al. 2003 Harris et al. 2016 Chen et al. 2020 Subtotal (95% CI) Heterogeneity: Tau ² = 0.33; Chi Test for overall effect: Z = 2.09 (Total (95% CI) Heterogeneity: Tau ² = 0.33; Chi Test for overall effect: Z = 2.09 (Test for overall effect: Z = 2.09 (Test for subgroup differences: N	Chi ² = 0.66, df = $\frac{1}{2}$ (A637 0.3379 0.1484 0.1622 1.311 0.1239 0.5596 0.1636 ² = 36.22, df = 3 ((P = 0.04) ² = 36.22, df = 3 ((P = 0.04) ³ = 36.22, df = 3 ((P = 0.04)	I (P = 0.42), <u>Weight I</u> 20.9% 26.1% 26.9% 26.1% 100.0% P < 0.00001] 100.0% P < 0.00001]	Risk Ratio V. Random. 95% CI Yr 1.59 [0.82, 3.08] 20 1.16 [0.84, 1.59] 20 1.77 [2.91, 4.73] 20 1.78 [1.47, 32] 1.89 [1.04, 3.42] t, I ^a = 92% 1.89 [1.04, 3.42] t, I ^a = 92%	Endometriosi ear IV. Ra 103 116 120 120 10.01 0.1 Endometrios Odd	s Endometriosis-free sk Ratio ndom. 95% CI the first state of the
Test for overall effect: Z = 4.02 Test for subgroup differences: (Study or Subgroup log[Ris 2.2.1 Cohort study Merrino et al. 2003 Harris et al. 2016 Chen et al. 2020 Xue et al. 2020 Subtotal (95% CI) Heterogeneity: Tau* = 0.33; Chi Test for overall effect: Z = 2.09 (Total (95% CI) Test for subgroup differences: N Studyory differences: N Study or Subgroup log[C	Chi ² = 0.66, df = $\frac{1}{2}$ (A637 0.3379 0.1484 0.1622 1.311 0.1239 0.5596 0.1636 ² = 36.22, df = 3 ((P = 0.04) ² = 36.22, df = 3 ((P = 0.04) ³ = 36.22, df = 3 ((P = 0.04)	I (P = 0.42), <u>Weight I</u> 20.9% 26.1% 26.9% 26.1% 100.0% P < 0.00001] 100.0% P < 0.00001]	Risk Ratio V. Random. 95% CI Yr 1.59 [0.82, 3.08] 2C 1.16 [0.84, 1.59] 2C 1.75 [1.27, 2.41] 2C 1.75 [1.27, 2.41] 2C 1.89 [1.04, 3.42] ; P = 92% 1.89 [1.04, 3.42] ; P = 92%	Endometriosi ear IV. Ra 103 116 120 120 10.01 0.1 Endometrios Odd	s Endometriosis-free
Test for overall effect: Z = 4.02 Test for subgroup differences: 0 Study or Subgroup log[Ris 2.2.1 Cohort study Merrino et al. 2003 Harris et al. 2016 Chen et al. 2020 Subtotal (95% CI) Heterogeneity: Tau ² = 0.33; Chi Test for overall effect: Z = 2.09 (Total (95% CI) Heterogeneity: Tau ² = 0.33; Chi Test for overall effect: Z = 2.09 (Total (95% CI) Heterogeneity: Tau ² = 0.33; Chi Test for overall effect: Z = 2.09 (Total (95% CI) Heterogeneity: Tau ² = 0.33; Chi Test for overall effect: Z = 2.09 (Total (95% CI) Heterogeneity: Tau ² = 0.33; Chi Test for overall effect: Z = 2.09 (Total (95% CI) Heterogeneity: Tau ² = 0.33; Chi Test for overall effect: Z = 2.09 (Test for subgroup differences: N Study or Subgroup Log[CG 3.1.1 Cross-sectional study	Chi ² = 0.66, df = $\frac{1}{2}$ (1.4637 0.3379 0.1484 0.1622 1.311 0.1239 0.5596 0.1636 $\frac{2}{3} = 36.22$, df = 3 ((P = 0.04) $\frac{2}{3} = 36.22$, df = 3 ((P = 0.04) Not applicable	I (P = 0.42), <u>Weight I</u> 20.9% 26.1% 100.0% P < 0.00001) 100.0% P < 0.00001) 004 SE IV.	Risk Ratio V. Random. 95% CI Yr 1.59 [0.82, 3.08] 2C 1.16 [0.84, 1.59] 2C 3.71 [2.91, 4.73] 2C 1.89 [1.04, 3.42] ; I ² = 92% 1.89 [1.04, 3.42] ; I ² = 92% ds Ratio Fixed, 95% CI Year	Endometriosi ear IV. Ra 103 116 120 120 10.01 0.1 Endometrios Odd	s Endometriosis-free sk Ratio ndom. 95% CI the first state of the
Test for overall effect: Z = 4.02 Test for subgroup differences: 0 Study or Subgroup log[Ris 2.2.1 Cohort study Merrino et al. 2003 Harris et al. 2016 Chen et al. 2020 Subtotal (95% CI) Heterogeneity: Tau ² = 0.33; Chi Test for overall effect: Z = 2.09 (Total (95% CI) Heterogeneity: Tau ² = 0.33; Chi Test for overall effect: Z = 2.09 (Total (95% CI) Heterogeneity: Tau ² = 0.33; Chi Test for overall effect: Z = 2.09 (Total (95% CI) Heterogeneity: Tau ² = 0.33; Chi Test for overall effect: Z = 2.09 (Total (95% CI) Heterogeneity: Tau ² = 0.33; Chi Test for overall effect: Z = 2.09 (Total (95% CI) Heterogeneity: Tau ² = 0.33; Chi Test for overall effect: Z = 2.09 (Test for subgroup differences: N Study or Subgroup Log[CG 3.1.1 Cross-sectional study	Chi ² = 0.66, df = $\frac{1}{2}$ (1.4637 0.3379 0.1484 0.1622 1.311 0.1239 0.5596 0.1636 $\frac{2}{3} = 36.22$, df = 3 ((P = 0.04) $\frac{2}{3} = 36.22$, df = 3 ((P = 0.04) Not applicable	I (P = 0.42), <u>Weight I</u> 20.9% 26.1% 100.0% P < 0.00001) 100.0% P < 0.00001) 004 SE IV.	Risk Ratio V. Random. 95% CI Yr 1.59 [0.82, 3.08] 20 1.16 [0.84, 1.59] 20 1.77 [2.91, 4.73] 20 1.78 [1.47, 32] 1.89 [1.04, 3.42] t, I ^a = 92% 1.89 [1.04, 3.42] t, I ^a = 92%	Endometriosi ear IV. Ra 103 116 120 120 10.01 0.1 Endometrios Odd	s Endometriosis-free sk Ratio ndom, 95% Cl t t t t t t t t t t t t t
Test for overall effect: Z = 4.02 Test for subgroup differences: 0 Study or Subgroup log[Ris 2.2.1 Cohort study Merrino et al. 2003 Harris et al. 2016 Chen et al. 2020 Subtotal (95% CI) Heterogeneity: Tau ² = 0.33; Chi Test for overall effect: Z = 2.09 (Total (95% CI) Heterogeneity: Tau ² = 0.33; Chi Test for overall effect: Z = 2.09 (Total (95% CI) Heterogeneity: Tau ² = 0.33; Chi Test for overall effect: Z = 2.09 (Total (95% CI) Heterogeneity: Tau ² = 0.33; Chi Test for overall effect: Z = 2.09 (Total (95% CI) Heterogeneity: Tau ² = 0.33; Chi Test for overall effect: Z = 2.09 (Total (95% CI) Heterogeneity: Tau ² = 0.33; Chi Test for overall effect: Z = 2.09 (Test for subgroup differences: N Study or Subgroup Log[CG 3.1.1 Cross-sectional study	Chi ² = 0.66, df = $\frac{1}{2}$ (1.4637 0.3379 0.1484 0.1622 1.311 0.1239 0.5596 0.1636 $\frac{2}{3} = 36.22$, df = 3 ((P = 0.04) $\frac{2}{3} = 36.22$, df = 3 ((P = 0.04) Not applicable	I (P = 0.42), <u>Weight I</u> 20.9% 26.1% 100.0% P < 0.00001) 100.0% P < 0.00001) 004 SE IV.	Risk Ratio V. Random. 95% CI Yr 1.59 [0.82, 3.08] 2C 1.16 [0.84, 1.59] 2C 3.71 [2.91, 4.73] 2C 1.75 [1.27, 2.41] 2L 1.89 [1.04, 3.42] r, P = 92% ds Ratio Fixed, 95% CI Year 15.55, 36.73] 2002	Endometrios R R IV. Ra 003 16 120 120 0.01 0.1 Endometrios Odd IV. Fixe	s Endometriosis-free
Test for overall effect: Z = 4.02 Test for subgroup differences: (Study or Subgroup log[Ris 2.2.1 Cohort study Merlino et al. 2003 Harris et al. 2016 Chen et al. 2020 Subtotal (95% CI) Heterogeneity: Tau ² = 0.33; Chi Test for overall effect: Z = 2.09 (Total (95% CI) Heterogeneity: Tau ² = 0.33; Chi Test for overall effect: Z = 2.09 (Test for overall effect: Z = 2.09 (Test for subgroup differences: N	Chi ² = 0.66, df = $\frac{1}{2}$ (1.4637 0.3379 0.1484 0.1622 1.311 0.1239 0.5596 0.1636 $\frac{2}{3} = 36.22$, df = 3 ((P = 0.04) $\frac{2}{3} = 36.22$, df = 3 ((P = 0.04) Not applicable	I (P = 0.42), <u>Weight I</u> 20.9% 26.1% 100.0% P < 0.00001) 100.0% P < 0.00001) 004 SE IV.	Risk Ratio V. Random. 95% CI Yr 1.59 [0.82, 3.08] 2C 1.16 [0.84, 1.59] 2C 3.71 [2.91, 4.73] 2C 1.75 [1.27, 2.41] 2L 1.89 [1.04, 3.42] r, P = 92% ds Ratio Fixed, 95% CI Year 15.55, 36.73] 2002	Endometriosi ear IV. Ra 103 116 120 120 10.01 0.1 Endometrios Odd	s Endometriosis-free
Test for overall effect: Z = 4.02 Test for subgroup differences: 0 Study or Subgroup log[Ris 2.2.1 Cohort study Merrino et al. 2003 Harris et al. 2016 Chen et al. 2020 Subtotal (95% CI) Heterogeneity: Tau² = 0.33; Chi Test for overall effect: Z = 2.09 (Total (95% CI) Heterogeneity: Tau² = 0.33; Chi Test for overall effect: Z = 2.09 (Total (95% CI) Heterogeneity: Tau² = 0.33; Chi Test for overall effect: Z = 2.09 (Total (95% CI) Heterogeneity: Tau² = 0.33; Chi Test for overall effect: Z = 2.09 (Total (95% CI) Heterogeneity: Tau² = 0.33; Chi Test for overall effect: Z = 2.09 (Test for subgroup differences: N Study or Subgroup Log[C 3.1.1 Cross-sectional study	Chi ² = 0.66, df = $\frac{1}{2}$ (1.4637 0.3379 0.1484 0.1622 1.311 0.1239 0.5596 0.1636 $\frac{2}{3} = 36.22$, df = 3 ((P = 0.04) $\frac{2}{3} = 36.22$, df = 3 ((P = 0.04) Not applicable	I (P = 0.42), <u>Weight I</u> 20.9% 26.1% 100.0% P < 0.00001) 100.0% P < 0.00001) 004 SE IV.	Risk Ratio V. Random. 95% CI Yı 1.59 [0.82, 3.08] 2C 1.16 [0.84, 1.59] 2C 3.71 [2.91, 4.73] 2C 1.75 [1.27, 2.41] 2C 1.89 [1.04, 3.42] ; P = 92% 1.89 [1.04, 3.42] ; P = 92% ds Ratio Fixed. 95% CI Year [15.55, 36.73] 2002	Endometriosi R R R V. Ra 003 116 120 120 0.01 0.1 Endometriosis 00d V. Fixe 0.01 0.1 Endometriosis	s Endometriosis-free
Test for overall effect. Z = 4.02 Test for subgroup differences: (Study or Subgroup log[Ris 2.2.1 Cohort study Merrino et al. 2003 Harris et al. 2016 Chen et al. 2020 Xue et al. 2020 Subtotal (95% CI) Heterogeneity: Tau ² = 0.33; Chi Test for overall effect. Z = 2.09 (Total (95% CI) Heterogeneity: Tau ² = 0.33; Chi Test for overall effect. Z = 2.09 (Total (95% CI) Test for subgroup differences: N Study or Subgroup log[C 3.1.1 Cross-sectional study Sinail et al. 2002	Chi ² = 0.66, df = $\frac{1}{2}$ 0.4637 0.3379 0.1484 0.1622 1.311 0.1239 0.5596 0.1636 ² = 36.22, df = 3 ((P = 0.04) ² = 36.22, df = 3 ((P = 0.04) ³ = 36.22, df = 3 (Chi = 3, 22, df = 3) (C = 0.04) 3.1739 0.2	I (P = 0.42), <u>Weight I</u> 20.9% 26.1% 26.9% 26.1% 100.0% P < 0.00001; 100.0% P < 0.00001; 000% SE IV. 193 23.90	Risk Ratio V. Random. 95% CI Yr 1.59 [0.82, 3.08] 20 1.16 [0.84, 1.59] 20 1.71 [2.91, 4.73] 20 1.76 [1.47, 2.41] 20 1.89 [1.04, 3.42] ; P = 92% 1.89 [1.04, 3.42] ; P = 92% ds Ratio Fixed, 95% CI Year [15.55, 36.73] 2002	Endometriosi R R IV. Ra 103 116 120 120 0.01 0.1 Endometriosis Risi	s Endometriosis-free sk Ratio ndom, 95% CI t t t t t t t t t t t t
Test for overall effect: 2 = 4.02 Test for subgroup differences: (Study or Subgroup log[Ris 2.2.1 Cohort study Merrino et al. 2003 Harris et al. 2016 Chen et al. 2020 Xue et al. 2020 Subtotal (95% CI) Heterogeneity: Tau ² = 0.33; Chi Test for overall effect: Z = 2.09 Total (95% CI) Heterogeneity: Tau ² = 0.33; Chi Test for overall effect: Z = 2.09 Total (95% CI) Test for subgroup differences: N Study or Subgroup log[C 3.1.1 Cross-sectional study Sinail et al. 2002	Chi ² = 0.66, df = $\frac{1}{2}$ (1.4637 0.3379 0.1484 0.1622 1.311 0.1239 0.5596 0.1636 $\frac{2}{3} = 36.22$, df = 3 ((P = 0.04) $\frac{2}{3} = 36.22$, df = 3 ((P = 0.04) Not applicable	I (P = 0.42), <u>Weight I</u> 20.9% 26.1% 100.0% P < 0.00001) 100.0% P < 0.00001) 004 SE IV.	Risk Ratio V. Random. 95% CI Yr 1.59 [0.82, 3.08] 20 1.16 [0.84, 1.59] 20 1.71 [2.91, 4.73] 20 1.76 [1.47, 2.41] 20 1.89 [1.04, 3.42] ; P = 92% 1.89 [1.04, 3.42] ; P = 92% ds Ratio Fixed, 95% CI Year [15.55, 36.73] 2002	Endometriosi R R IV. Ra 103 116 120 120 0.01 0.1 Endometriosis Risi	s Endometriosis-free
Test for overall effect: 2 = 4.02 Test for subgroup differences: 0 Study or Subgroup log[Ris 2.2.1 Cohort study Merrino et al. 2003 Harris et al. 2016 Chen et al. 2020 Xue et al. 2020 Subtotal (95% C1) Heterogeneity: Tau* = 0.33; Chi Test for overall effect: Z = 2.09 (Test for subgroup differences: N Study or Subgroup log[C Study or Subgroup log[C Sinaii et al. 2002	Chi ² = 0.66, df = $\frac{1}{2}$ ik Ratio] SE 0.4637 0.3379 0.1484 0.1622 1.311 0.1239 0.5596 0.1636 $\frac{2}{2} = 36.22$, df = 3 ((P = 0.04) ict applicable Odds Ratio] 3.1739 0.2 Risk Ratio]	I (P = 0.42), Weight I 20.9% 26.1% 26.1% 26.1% 100.0% P < 0.00001; 100.0% P < 0.00001; 100.0% P < 0.00001; 100.0% SE IV, ISSE Weight	Risk Ratio V. Random. 95% CI Yr 1.59 [0.82, 3.08] 2C 1.16 [0.84, 1.59] 2C 1.75 [1.27, 2.41] 2C 1.89 [1.04, 3.42] Y ^P = 92% 1.89 [1.04, 3.42] Y ^P = 92% ds Ratio Fixed. 95% CI Year [15.55, 36.73] 2002 Risk Ratio t IV. Fixed. 95% CI	Endometriosi R R IV. Ra 103 116 120 120 0.01 0.1 Endometriosis Risi	s Endometriosis-free sk Ratio ndom, 95% CI t t t t t t t t t t t t
Test for overall effect: Z = 4.02 Test for subgrouplog[Ris 2.2.1 Cohort study Merrino et al. 2003 Harris et al. 2016 Chen et al. 2020 Xue et al. 2020 Subtotal (95% CI) Heterogeneity: Tau² = 0.33; Chi Test for overall effect: Z = 2.09 (Total (95% CI) Heterogeneity: Tau² = 0.33; Chi Test for overall effect: Z = 2.09 (Total (95% CI) Heterogeneity: Tau² = 0.33; Chi Test for overall effect: Z = 2.09 (Total (95% CI) Heterogeneity: Tau² = 0.33; Chi Test for overall effect: Z = 2.09 (Tostal (95% CI) Heterogeneity: Tau² = 0.33; Chi Test for overall effect: Z = 2.09 (Tostal (95% CI) Heterogeneity: Tau² = 0.33; Chi Test for overall effect: Z = 2.09 (Test for subgroup	Chi ² = 0.66, df = $\frac{1}{2}$ 0.4637 0.3379 0.1484 0.1622 1.311 0.1239 0.5596 0.1636 ² = 36.22, df = 3 ((P = 0.04) ² = 36.22, df = 3 ((P = 0.04) ³ = 36.22, df = 3 (Chi = 3, 22, df = 3) (C = 0.04) 3.1739 0.2	I (P = 0.42), Weight I 20.9% 26.1% 26.9% 26.1% 100.0% P < 0.00001; 100.0% P < 0.00001; 100.0% SE IV. 193 23.90 SE Weight D66 72.09	Risk Ratio V. Random. 95% CI Yr 1.59 [0.82, 3.08] 2C 1.16 [0.84, 1.59] 2C 3.71 [2.91, 4.73] 2C 1.75 [1.47, 2.41] 2C 1.89 [1.04, 3.42] 1; F = 92% ds Ratio Fixed, 95% CI Year 15.55, 36.73] 2002 Risk Ratio t_V, Fixed, 95% CI 0 14.55, 1.27, 1.65]	Endometriosi R R IV. Ra 103 116 120 120 0.01 0.1 Endometriosis Risi	s Endometriosis-free sk Ratio ndom. 95% CI t t t t t t t t t t t t
Test for overall effect: 2 = 4.02 Test for subgroup differences: 0 Study or Subgroup log[Ris 2.2.1 Cohort study Merrino et al. 2003 Harris et al. 2016 Chen et al. 2020 Subtotal (95% CI) Heterogeneity: Tau ² = 0.33; Chi Test for overall effect: Z = 2.09; Total (95% CI) Heterogeneity: Tau ² = 0.33; Chi Test for overall effect: Z = 2.09; Total (95% CI) Heterogeneity: Tau ² = 0.33; Chi Test for subgroup differences: N Study or Subgroup log[C 3.1.1 Cross-sectional study Sinali et al. 2002 Study or Subgroup log[C 3.2.1 Cohort study Chao et al. 2022	Chi ² = 0.66, df = $-$ (k Ratio] SE 0.4637 0.3379 0.1484 0.1622 1.311 0.1239 0.5596 0.1636 ² = 36.22, df = 3 ((P = 0.04) ² = 36.22, df = 3 ((P = 0.04) ³ = 36.22, df = 3 ((P = 0.04) 3.1739 0.2 Chi Chi Chi Chi Chi Chi Chi Chi	I (P = 0.42), Weight I 20.9% 26.1% 26.9% 26.1% 100.0% P < 0.00001; 100.0% P < 0.00001; 100.0% SE IV. 193 23.90 SE Weight D66 72.09	Risk Ratio V. Random. 95% CI Yr 1.59 [0.82, 3.08] 2C 1.16 [0.84, 1.59] 2C 3.71 [2.91, 4.73] 2C 1.75 [1.27, 2.41] 2C 1.89 [1.04, 3.42] r, P = 92% ds Ratio Fixed. 95% CI Year [15.55, 36.73] 2002 Risk Ratio t.V. Fixed. 95% CI (1.30, 1.97] 6 1.45 [1.27, 1.65] 6 1.45 [1.30, 1.97]	Endometriosi R R IV. Ra 103 116 120 120 0.01 0.1 Endometriosis Risi	s Endometriosis-free sk Ratio ndom. 95% CI t t t t t t t t t t t t
Test for overall effect: 2 = 4.02 Test for subgroup differences: 0 Study or Subgroup log[Ris 2.2.1 Cohort study Merrino et al. 2003 Harris et al. 2016 Chen et al. 2020 Xue et al. 2020 Subtotal (95% CI) Heterogeneity: Tau* = 0.33; Chi Test for overall effect: Z = 2.09 (Total (95% CI) Heterogeneity: Tau* = 0.33; Chi Test for subgroup differences: N Study or Subgroup log[C 3.1.1 Cross-sectional study Sinaii et al. 2002 Study or Subgroup log[C 3.2.1 Cohort study Chao et al. 2022 Nietgen et al. 2011 Subtotal (95% CI)	Chi ² = 0.66, df = $\frac{1}{2}$ (A637 0.3379 0.1484 0.1622 1.311 0.1239 0.5596 0.1636 2^{2} = 36.22, df = 3 ((P = 0.04) 2^{2} = 36.22, df = 3 ((P = 0.04) 3.1739 0.2 Not applicable Not appli	I (P = 0.42), Weight I 20.9% 26.1% 26.9% 26.1% 100.0% P < 0.00001; 100.0% P < 0.00001; 100.0% SE IV. 193 23.90 SE Weight 066 72.09 059 28.09 100.05	Risk Ratio V. Random. 95% CI Yr 1.59 [0.82, 3.08] 2C 1.16 [0.84, 1.59] 2C 3.71 [2.91, 4.73] 2C 1.75 [1.27, 2.41] 2C 1.89 [1.04, 3.42] r, P = 92% ds Ratio Fixed. 95% CI Year [15.55, 36.73] 2002 Risk Ratio t.V. Fixed. 95% CI (1.30, 1.97] 6 1.45 [1.27, 1.65] 6 1.45 [1.30, 1.97]	Endometriosi R R IV. Ra 103 116 120 120 0.01 0.1 Endometriosis Risi	s Endometriosis-free sk Ratio ndom, 95% CI t t t t t t t t t t t t
Test for overall effect: 2 = 4.02 Test for subgroup differences: 0 Study or Subgroup log[Ris 2.2.1 Cohort study Merrino et al. 2003 Harris et al. 2016 Chen et al. 2020 Xue et al. 2020 Subtotal (95% C1) Heterogeneity: Tau ² = 0.33; Chi Test for overall effect: Z = 2.09 Total (95% C1) Heterogeneity: Tau ² = 0.33; Chi Test for overall effect: Z = 2.09 Total (95% C1) Heterogeneity: Tau ² = 0.33; Chi Test for subgroup indifferences: N Study or Subgroup indifferences: N Study or Subgroup indifferences: N Shindi et al. 2002 Shindi et al. 2002 Study or Subgroup indifferences: N Shindi et al. 2002 Shindi et al. 2002 Ninia et al. 2002 Nielsen et al. 2011 Subtotal (95% C1)	Chi ² = 0.66, df = $\frac{1}{2}$ (A637 0.3379 0.1484 0.1622 1.311 0.1239 0.5596 0.1636 2^{2} = 36.22, df = 3 ((P = 0.04) 2^{2} = 36.22, df = 3 ((P = 0.04) 3.1739 0.2 Not applicable Not appli	I (P = 0.42), Weight I 20.9% 26.1% 26.9% 26.1% 100.0% P < 0.00001; 100.0% P < 0.00001; 100.0% SE IV. 193 23.90 SE Weight 066 72.09 059 28.09 100.05	Risk Ratio V. Random. 95% CI Yr 1.59 [0.82, 3.08] 2C 1.16 [0.84, 1.59] 2C 3.71 [2.91, 4.73] 2C 1.75 [1.27, 2.41] 2C 1.89 [1.04, 3.42] r, P = 92% ds Ratio Fixed. 95% CI Year [15.55, 36.73] 2002 Risk Ratio t.V. Fixed. 95% CI (1.30, 1.97] 6 1.45 [1.27, 1.65] 6 1.45 [1.30, 1.97]	Endometriosi R R IV. Ra 103 116 120 120 0.01 0.1 Endometriosis Risi	s Endometriosis-free sk Ratio ndom. 95% CI t t t t t t t t t t t t
Test for overall effect: 2 = 4.02 Test for subgroup differences: (Study or Subgroup log[Ris 2.2.1 Cohort study Merrino et al. 2003 Harris et al. 2016 Chen et al. 2020 Subtotal (95% CI) Heterogeneity: Tau ² = 0.33; Chi Test for overall effect: Z = 2.09; Total (95% CI) Heterogeneity: Tau ² = 0.33; Chi Test for overall effect: Z = 2.09; Total (95% CI) Heterogeneity: Tau ² = 0.33; Chi Test for subgroup differences: N Study or Subgroup log[C 3.1.1 Cross-sectional study Sinaii et al. 2002 Study or Subgroup log[C 3.2.1 Cohort study Chao et al. 2022 Nielsen et al. 2021 Nielsen et al. 2021 Nielsen et al. 2021 Subtotal (95% CI) Heterogeneity: Chi ² = 0.62; di Test for overall effect: Z = 7.1	Chi ² = 0.66, df = $\frac{1}{2}$ (A637 0.3379 0.1484 0.1622 1.311 0.1239 0.5596 0.1636 2^{2} = 36.22, df = 3 ((P = 0.04) 2^{2} = 36.22, df = 3 ((P = 0.04) 3.1739 0.2 Not applicable Not appli	I (P = 0.42), Weight I 20.9% 26.1% 26.9% 26.1% 100.0% P < 0.00001; 100.0% P < 0.00001; 100.0% SE IV. 193 23.90 SE Weigh D66 72.09 159 28.09 100.0% P < 0.0000; 100.0%	Risk Ratio V. Random. 95% CI Yr 1.59 [0.82, 3.08] 2C 1.16 [0.84, 1.59] 2C 3.71 [2.91, 4.73] 2C 1.75 [1.47, 2.41] 2C 1.89 [1.04, 3.42] ; P = 92% 1.89 [1.04, 3.42] ; F = 92% ds Ratio Fixed, 95% CI Year [15.55, 36.73] 2002 Risk Ratio t_V, Fixed, 95% CI 6 1.45 [1.27, 1.65] 5 6 1.49 [1.34, 1.66] 1.49 [1.34, 1.66]	Endometriosi R R IV. Ra 103 116 120 120 0.01 0.1 Endometriosis Risi	s Endometriosis-free sk Ratio ndom. 95% CI t t t t t t t t t t t t
Test for overall effect: 2 = 4.02 Test for subgroup differences: 0 Study or Subgroup log[Ris 2.2.1 Cohort study Merrino et al. 2003 Harris et al. 2016 Chen et al. 2020 Xue et al. 2020 Subtotal (95% CI) Heterogeneity: Tau* = 0.33; Chi Test for overall effect: Z = 2.09 (Total (95% CI) Heterogeneity: Tau* = 0.33; Chi Test for subgroup differences: N Study or Subgroup log[C 3.1.1 Cross-sectional study Sinaii et al. 2002 Study or Subgroup log[C 3.2.1 Cohort study Chao et al. 2022 Nietgen et al. 2011 Subtotal (95% CI)	Chi ² = 0.66, df = $(-1)^{-1}$ (k Ratio) SE 0.4637 0.3379 0.1484 0.1622 1.311 0.1239 0.5596 0.1636 (P = 0.04) ² = 36.22, df = 3 ((P = 0.04) ² = 36.22, df = 3 ((P = 0.04) ² = 36.22, df = 3 ((P = 0.04) (P = 0.04) (A = 0.00001) (A = 0.00001)	I (P = 0.42), Weight I 20.9% 26.1% 26.9% 26.1% 100.0% P < 0.00001; 100.0% P < 0.00001; 103 23.90 SE Weight 066 72.09 100.09 100.09 100.09	Risk Ratio V. Random. 95% CI Yr 1.59 [0.82, 3.08] 2C 1.16 [0.84, 1.59] 2C 3.71 [2.91, 4.73] 2C 1.75 [1.47, 2.41] 2C 1.89 [1.04, 3.42] ; P = 92% 1.89 [1.04, 3.42] ; F = 92% ds Ratio Fixed, 95% CI Year [15.55, 36.73] 2002 Risk Ratio t_V, Fixed, 95% CI 6 1.45 [1.27, 1.65] 5 6 1.49 [1.34, 1.66] 1.49 [1.34, 1.66]	Endometriosi R R IV. Ra 103 116 120 120 0.01 0.1 Endometriosis Risi	s Endometriosis-free sk Ratio ndom. 95% CI t t t t t t t t t t t t

Fig. 3 Forest plots of studies. (A) the association of endometriosis with SLE risk; (B) the association of endometriosis with RA risk; (C) the association of endometriosis with SS risk

Diseases	Method	OR(95%CI)	P-value
SLE	MR Egger	1.5885(0.392,6.4369)	0.522
SLE	Weighted median	1.6993(0.8445,3.4196)	0.148
SLE	Inverse variance weighted	1.9149(1.2043,3.0449)	0.006
SLE	Simple mode	1.0588(0.3366,3.3307)	0.926
SLE	Weighted mode	1.363(0.6255,2.9699)	0.455
RA	MR Egger	1.0049(0.9917,1.0182)	0.476
RA	Weighted median	1.0079(1.0022,1.0136)	0.007
RA	Inverse variance weighted	1.0049(1.001,1.0089)	0.014
RA	Simple mode	1.0097(0.9974,1.0221)	0.126
RA	Weighted mode	1.0092(0.9996,1.019)	0.056
SS	MR Egger	0.3474(0.0508,2.3774)	0.993
SS	Weighted median	1.3657(0.5817,3.2067)	0.291
SS	Inverse variance weighted	1.1919(0.6594,2.1543)	0.598
SS	Simple mode	0.5884(0.0859,4.0304)	0.593
SS	Weighted mode	0.359(0.052,2.4769)	0.306
		0 1 2 3	4 5 6 7

Fig. 4 Associations of genetic predisposition to endometriosis with SLE, RA, and SS risk

the MR-Egger nor the MR-PRESSO analyses revealed any indication of horizontal pleiotropy, indicating a very low level of pleiotropic bias. Secondly, the observational studies collected in our meta-analysis did not consider the influence of mediation effects. For example, patients with endometriosis exhibited an increased susceptibility to sedentary behavior [3]. Sedentary behavior is also acknowledged as a risk factor for autoimmune diseases [55]. Finally, our study did not examine the effect of endometriosis on the prognosis of autoimmune disorders due to a lack of data. Therefore, more studies are warranted to elucidate the possible relation between the two conditions.

Abbreviations

Fig	Figure
GWAS	Genome-wide association study
IVW	Inverse-variance-weighted
MR	Mendelian randomization

Supplementary Information

The online version contains supplementary material available at https://doi. org/10.1186/s12884-024-06347-9.

Supplementary Material 1.

Supplementary Material 2.

Supplementary Material 3.

Authors' contributions

Conceptualization: T.Y.T. Software: T.Y.T. Data curation: H.L.Y. and Y.Z. Writing – original draft: T.Y.T. Visualization: S.P.X. The work reported in the paper has been performed by the authors, unless clearly specified in the text. All authors reviewed the manuscript.

Funding

This work was supported by National innovation and entrepreneurship training program [SRIEP202104].

Availability of data and materials

The 42 SNPs selected for endometriosis are provided in Datasheet2 Table S1. The data that support the findings of this study are openly available in an open website (https://gwas.mrcieu.ac.uk/). All data generated or analysed during this study are included in this published article and datasheet.

Declarations

Ethics approval statement and consent to participate

The data we used were obtained from published studies approved by the corresponding ethics committee, thus no further ethical approval was required for this study.

Consent for publication

Not applicable.

Competing interests

The authors declare no competing interests.

Received: 20 September 2023 Accepted: 13 February 2024 Published online: 23 February 2024

References

- Giudice LC, Kao LC. Endometriosis Lancet. 2004;364:1789–99. https://doi. org/10.1016/S0140-6736(04)17403-5.
- Koller D, Pathak GA, Wendt FR, Tylee DS, Levey DF, Overstreet C, et al. Epidemiologic and Genetic Associations of Endometriosis With Depression, Anxiety, and Eating Disorders. JAMA Netw Open. 2023;6: e2251214. https://doi.org/10.1001/jamanetworkopen.2022.51214.
- Parazzini F, Esposito G, Tozzi L, Noli S, Bianchi S. Epidemiology of endometriosis and its comorbidities. Eur J Obstet Gynecol Reprod Biol. 2017;209:3–07. https://doi.org/10.1016/j.ejogrb.2016.04.021.
- Burney RO, Giudice LC. Pathogenesis and pathophysiology of endometriosis. Fertil Steril. 2012;98:511–9. https://doi.org/10.1016/j.fertnstert.2012. 06.029.
- Wang L, Wang FS, Gershwin ME. Human autoimmune diseases: a comprehensive update. J Intern Med. 2015;278:369–95. https://doi.org/10. 1111/joim.12395.
- Paul DW, Braun DP. Immunology of endometriosis. Best Pract Res Clin Obstet Gynaecol. 2004;18:245–63. https://doi.org/10.1016/j.bpobgyn. 2004.02.001.

- Symons LK, Miller JE, Kay VR, Marks RM, Liblik K, Koti M, et al. The Immunopathophysiology of Endometriosis. Trends Mol Med. 2018;24:748–62. https://doi.org/10.1016/j.molmed.2018.07.004.
- Burgess S, Butterworth A, Thompson SG. Mendelian randomization analysis with multiple genetic variants using summarized data. Genet Epidemiol. 2013;37:658–65. https://doi.org/10.1002/gepi.21758.
- Lawlor DA, Harbord RM, Sterne JA, Timpson N, Davey SG. Mendelian randomization: using genes as instruments for making causal inferences in epidemiology. Stat Med. 2008;27:1133–63. https://doi.org/10.1002/sim. 3034.
- Smith GD, Ebrahim S. "Mendelian randomization": can genetic epidemiology contribute to understanding environmental determinants of disease? Int J Epidemiol. 2003;32:1–22. https://doi.org/10.1093/ije/dyg070.
- 11. Moher D, Liberati A, Tetzlaff J, Altman DG. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. Plos Med. 2009;6: e1000097. https://doi.org/10.1371/journal.pmed.1000097.
- Norris JM, Simpson BS, Ball R, Freeman A, Kirkham A, Parry MA, et al. A Modified Newcastle-Ottawa Scale for Assessment of Study Quality in Genetic Urological Research. Eur Urol. 2021;79:325–6. https://doi.org/10. 1016/j.eururo.2020.12.017.
- Soffin EM, Gibbons MM, Ko CY, Kates SL, Wick E, Cannesson M, et al. Evidence Review Conducted for the Agency for Healthcare Research and Quality Safety Program for Improving Surgical Care and Recovery: Focus on Anesthesiology for Total Knee Arthroplasty. Anesth Analg. 2019;128:441–53. https://doi.org/10.1213/ANE.00000000003564.
- Greenland S. Quantitative methods in the review of epidemiologic literature. Epidemiol Rev. 1987;9:1–30. https://doi.org/10.1093/oxfordjournals. epirev.a036298.
- Siristatidis C, Sergentanis TN, Kanavidis P, Trivella M, Sotiraki M, Mavromatis I, et al. Controlled ovarian hyperstimulation for IVF: impact on ovarian, endometrial and cervical cancer–a systematic review and meta-analysis. Hum Reprod Update. 2013;19:105–23. https://doi.org/10.1093/humupd/ dms051.
- Rahmioglu N, Mortlock S, Ghiasi M, Møller PL, Stefansdottir L, Galarneau G, et al. The genetic basis of endometriosis and comorbidity with other pain and inflammatory conditions. Nat Genet. 2023;55:423–36. https:// doi.org/10.1038/s41588-023-01323-z.
- Wang YF, Zhang Y, Lin Z, Zhang H, Wang TY, Cao Y, et al. Identification of 38 novel loci for systemic lupus erythematosus and genetic heterogeneity between ancestral groups. Nat Commun. 2021;12:772. https://doi.org/ 10.1038/s41467-021-21049-y.
- Bowden J, Del GMF, Minelli C, Davey SG, Sheehan N, Thompson J. A framework for the investigation of pleiotropy in two-sample summary data Mendelian randomization. Stat Med. 2017;36:1783–802. https://doi. org/10.1002/sim.7221.
- Yang J, Ferreira T, Morris AP, Medland SE, Madden PA, Heath AC, et al. Conditional and joint multiple-SNP analysis of GWAS summary statistics identifies additional variants influencing complex traits. Nat Genet. 2012;44(369–75):S1-03. https://doi.org/10.1038/ng.2213.
- Bowden J, Davey SG, Haycock PC, Burgess S. Consistent Estimation in Mendelian Randomization with Some Invalid Instruments Using a Weighted Median Estimator. Genet Epidemiol. 2016;40:304–14. https:// doi.org/10.1002/gepi.21965.
- Bowden J, Davey SG, Burgess S. Mendelian randomization with invalid instruments: effect estimation and bias detection through Egger regression. Int J Epidemiol. 2015;44:512–25. https://doi.org/10.1093/ije/dyv080.
- Verbanck M, Chen CY, Neale B, Do R. Detection of widespread horizontal pleiotropy in causal relationships inferred from Mendelian randomization between complex traits and diseases. Nat Genet. 2018;50:693–8. https:// doi.org/10.1038/s41588-018-0099-7.
- Burgess S, Thompson SG. Interpreting findings from Mendelian randomization using the MR-Egger method. Eur J Epidemiol. 2017;32:377–89. https://doi.org/10.1007/s10654-017-0255-x.
- Fan YH, Leong PY, Chiou JY, Wang YH, Ku MH, Wei JC. Association between endometriosis and risk of systemic lupus erythematosus. Sci Rep. 2021;11:532. https://doi.org/10.1038/s41598-020-79954-z.
- Harris HR, Costenbader KH, Mu F, Kvaskoff M, Malspeis S, Karlson EW, et al. Endometriosis and the risks of systemic lupus erythematosus and rheumatoid arthritis in the Nurses' Health Study II. Ann Rheum Dis. 2016;75:1279–84. https://doi.org/10.1136/annrheumdis-2015-207704.

- Lin YH, Yang YC, Chen SF, Hsu CY, Shen YC. Risk of systemic lupus erythematosus in patients with endometriosis: A nationwide population-based cohort study. Arch Gynecol Obstet. 2020;302:1197–203. https://doi.org/ 10.1007/s00404-020-05726-9.
- Matorras R, Ocerin I, Unamuno M, Nieto A, Peiró E, Burgos J, et al. Prevalence of endometriosis in women with systemic lupus erythematosus and Sjogren's syndrome. Lupus. 2007;16:736–40. https://doi.org/10.1177/ 0961203307081339.
- Nielsen NM, Jørgensen KT, Pedersen BV, Rostgaard K, Frisch M. The co-occurrence of endometriosis with multiple sclerosis, systemic lupus erythematosus and Sjogren syndrome. Hum Reprod. 2011;26:1555–9. https://doi.org/10.1093/humrep/der105.
- 29. Porpora MG, Scaramuzzino S, Sangiuliano C, Piacenti I, Bonanni V, Piccioni MG, et al. High prevalence of autoimmune diseases in women with endometriosis: a case-control study. Gynecol Endocrinol. 2020;36:356–9. https://doi.org/10.1080/09513590.2019.1655727.
- Sinaii N, Cleary SD, Ballweg ML, Nieman LK, Stratton P. High rates of autoimmune and endocrine disorders, fibromyalgia, chronic fatigue syndrome and atopic diseases among women with endometriosis: a survey analysis. Hum Reprod. 2002;17:2715–24. https://doi.org/10.1093/humrep/ 17.10.2715.
- Yoshii E, Yamana H, Ono S, Matsui H, Yasunaga H. Association between allergic or autoimmune diseases and incidence of endometriosis: A nested case-control study using a health insurance claims database. Am J Reprod Immunol. 2021;86: e13486. https://doi.org/10.1111/aji.13486.
- Chen SF, Yang YC, Hsu CY, Shen YC. Risk of Rheumatoid Arthritis in Patients with Endometriosis: A Nationwide Population-Based Cohort Study. J Womens Health (Larchmt). 2021;30:1160–4. https://doi.org/10. 1089/jwh.2020.8431.
- Merlino LA, Cerhan JR, Criswell LA, Mikuls TR, Saag KG. Estrogen and other female reproductive risk factors are not strongly associated with the development of rheumatoid arthritis in elderly women. Semin Arthritis Rheum. 2003;33:72–82. https://doi.org/10.1016/s0049-0172(03)00084-2.
- Xue YH, You LT, Ting HF, Chen YW, Sheng ZY, Xie YD, et al. Increased risk of rheumatoid arthritis among patients with endometriosis: a nationwide population-based cohort study. Rheumatology (Oxford). 2021;60:3326–33. https://doi.org/10.1093/rheumatology/keaa784.
- Chao YH, Liu CH, Pan YA, Yen FS, Chiou JY, Wei JC. Association Between Endometriosis and Subsequent Risk of Sjögren's Syndrome: A Nationwide Population-Based Cohort Study. Front Immunol. 2022;13: 845944. https://doi.org/10.3389/fimmu.2022.845944.
- Shigesi N, Kvaskoff M, Kirtley S, Feng Q, Fang H, Knight JC, et al. The association between endometriosis and autoimmune diseases: a systematic review and meta-analysis. Hum Reprod Update. 2019;25:486–503. https://doi.org/10.1093/humupd/dmz014.
- McLeod BS, Retzloff MG. Epidemiology of endometriosis: an assessment of risk factors. Clin Obstet Gynecol. 2010;53:389–96. https://doi.org/10. 1097/GRE.0b013e3181db7bde.
- Xiao XY, Chen Q, Shi YZ, Li LW, Hua C, Zheng H. Risk factors of systemic lupus erythematosus: an overview of systematic reviews and Mendelian randomization studies. Adv Rheumatol. 2023;63:42. https://doi.org/10. 1186/s42358-023-00323-1.
- Kolanska K, Alijotas-Reig J, Cohen J, Cheloufi M, Selleret L, D'Argent E, et al. Endometriosis with infertility: A comprehensive review on the role of immune deregulation and immunomodulation therapy. Am J Reprod Immunol. 2021;85: e13384. https://doi.org/10.1111/ajj.13384.
- Vanni VS, Villanacci R, Salmeri N, Papaleo E, Delprato D, Ottolina J, et al. Concomitant autoimmunity may be a predictor of more severe stages of endometriosis. Sci Rep. 2021;11:15372. https://doi.org/10.1038/ s41598-021-94877-z.
- Khizroeva J, Nalli C, Bitsadze V, Lojacono A, Zatti S, Andreoli L, et al. Infertility in women with systemic autoimmune diseases. Best Pract Res Clin Endocrinol Metab. 2019;33: 101369. https://doi.org/10.1016/j.beem.2019. 101369.
- Guo SW, Du Y, Liu X. Platelet-derived TGF-β1 mediates the down-modulation of NKG2D expression and may be responsible for impaired natural killer (NK) cytotoxicity in women with endometriosis. Hum Reprod. 2016;31:1462–74. https://doi.org/10.1093/humrep/dew057.
- 43. Kang YJ, Jeung IC, Park A, Park YJ, Jung H, Kim TD, et al. An increased level of IL-6 suppresses NK cell activity in peritoneal fluid of patients

with endometriosis via regulation of SHP-2 expression. Hum Reprod. 2014;29:2176–89. https://doi.org/10.1093/humrep/deu172.

- 44. Yu JJ, Sun HT, Zhang ZF, Shi RX, Liu LB, Shang WQ, et al. IL15 promotes growth and invasion of endometrial stromal cells and inhibits killing activity of NK cells in endometriosis. Reproduction. 2016;152:151–60. https://doi.org/10.1530/REP-16-0089.
- Berbic M, Schulke L, Markham R, Tokushige N, Russell P, Fraser IS. Macrophage expression in endometrium of women with and without endometriosis. Hum Reprod. 2009;24:325–32. https://doi.org/10.1093/ humrep/den393.
- 46. Milewski Ł, Dziunycz P, Barcz E, Radomski D, Roszkowski PI, Korczak-Kowalska G, et al. Increased levels of human neutrophil peptides 1, 2, and 3 in peritoneal fluid of patients with endometriosis: association with neutrophils, T cells and IL-8. J Reprod Immunol. 2011;91:64–70. https:// doi.org/10.1016/j.jri.2011.05.008.
- Riccio L, Baracat EC, Chapron C, Batteux F, Abrão MS. The role of the B lymphocytes in endometriosis: A systematic review. J Reprod Immunol. 2017;123:29–34. https://doi.org/10.1016/j.jri.2017.09.001.
- Dang VD, Stefanski AL, Lino AC, Dörner T. B- and Plasma Cell Subsets in Autoimmune Diseases: Translational Perspectives. J Invest Dermatol. 2022;142:811–22. https://doi.org/10.1016/j.jid.2021.05.038.
- Fresneda AM, McLaren Z, Wright HL. Neutrophils in the Pathogenesis of Rheumatoid Arthritis and Systemic Lupus Erythematosus: Same Foe Different M.O. Front Immunol 2021;12:649693. https://doi.org/10.3389/ fimmu.2021.649693
- 50. Zhang C, Tian Z. NK cell subsets in autoimmune diseases. J Autoimmun. 2017;83:22–30. https://doi.org/10.1016/j.jaut.2017.02.005.
- Marquardt RM, Kim TH, Shin JH, Jeong JW. Progesterone and Estrogen Signaling in the Endometrium: What Goes Wrong in Endometriosis? Int J Mol Sci 2019;20. https://doi.org/10.3390/ijms20153822
- Dolmans MM, Donnez J. Emerging Drug Targets for Endometriosis. Biomolecules 2022;12. https://doi.org/10.3390/biom12111654
- Merrheim J, Villegas J, Van Wassenhove J, Khansa R, Berrih-Aknin S, le Panse R, et al. Estrogen, estrogen-like molecules and autoimmune diseases. Autoimmun Rev. 2020;19: 102468. https://doi.org/10.1016/j.autrev. 2020.102468.
- Hughes GC, Choubey D. Modulation of autoimmune rheumatic diseases by oestrogen and progesterone. Nat Rev Rheumatol. 2014;10:740–51. https://doi.org/10.1038/nrrheum.2014.144.
- Pinto AJ, Roschel H, de Sá PA, Lima FR, Pereira R, Silva CA, et al. Physical inactivity and sedentary behavior: Overlooked risk factors in autoimmune rheumatic diseases? Autoimmun Rev. 2017;16:667–74. https://doi.org/10. 1016/j.autrev.2017.05.001.

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.